Advertisement

Psychopharmacology

, Volume 187, Issue 3, pp 284–286 | Cite as

Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.

  • David E. NicholsEmail author
Commentary

The article by Griffiths et al. in this issue of Psychopharmacology should make all scientists interested in human psychopharmacology sit up and take notice. It is the first well-designed, placebo-controlled, clinical study in more than four decades to examine the psychological consequences of the effects of the hallucinogenic (psychedelic) agent known as psilocybin. In fact, one would be hard-pressed to find a single study of psychedelics from any earlier era that was as well-done or as meaningful. Perhaps more importantly, despite the notion by many people that psychedelics are nothing more than troublesome drugs of abuse, the present study convincingly demonstrates that, when used appropriately, these compounds can produce remarkable, possibly beneficial, effects that certainly deserve further study.

Although many people seem to believe that “psychedelics” simply appeared during the turbulent 1960s, in fact the use of these materials spans back through many millennia of human...

Keywords

Psilocybin Terminal Cancer Patient Psychedelic Drug Theological Seminary Transcendental State 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Grof S, Goodman LE, Richards WA, Kurland AA (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8:129–144PubMedGoogle Scholar
  2. Huxley A (1970) The Doors of Perception. Perenial Library, New YorkGoogle Scholar
  3. Kast E (1966) LSD and the dying patient. Chic Med Sch Q 26:80–87PubMedGoogle Scholar
  4. Kast EC, Collins VJ (1964) Lysergic acid diethylamide as an analgesic agent. Anesth Analg 43:285–291PubMedCrossRefGoogle Scholar
  5. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181PubMedCrossRefGoogle Scholar
  6. Pahnke WN, Kurland AA, Goodman LE, Richards WA (1969) LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 9:144–152PubMedGoogle Scholar
  7. Pahnke WN, Kurland AA, Unger S, Savage C, Grof S (1970a) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212:1856–1863PubMedCrossRefGoogle Scholar
  8. Pahnke WN, Kurland AA, Unger S, Savage C, Wolff MC, Goodman LE (1970b) Psychedelic therapy (utilizing LSD) with cancer patients. J Psychedelic Drugs 3:63–75Google Scholar
  9. Schultes RE, Hofmann A (1979) Plants of the gods. Origins of hallucinogenic use. Alfred van der Marck Editions, New YorkGoogle Scholar
  10. Strassman RJ (1996) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 73:121–124PubMedCrossRefGoogle Scholar
  11. Strassman RJ, Qualls CR (1994) Dose–response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51:85–97PubMedGoogle Scholar
  12. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose–response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Medicinal Chemistry and Molecular PharmacologyPurdue University School of Pharmacy and Pharmaceutical SciencesWest LafayetteUSA

Personalised recommendations